Improved Long-Term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab

BACKGROUND & AIMS: Monitoring serum concentrations of tumor necrosis factor antagonists in patients receiving these drugs as treatment for inflammatory bowel disease (IBD), also called therapeutic drug monitoring, is performed either after patient loss of response (reactive drug monitoring) or i...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Gastroenterol Hepatol
Autori principali: Papamichael, Konstantinos, Chachu, Karen A., Vajravelu, Ravy, Vaughn, Byron P., Ni, Josephine, Osterman, Mark T., Cheifetz, Adam S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2017
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5605429/
https://ncbi.nlm.nih.gov/pubmed/28365486
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cgh.2017.03.031
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi